GKSL Q3FY26 Results: Standalone Profit ₹233.26 Lakhs, Consolidated Profit ₹370.62 Lakhs
Gujarat Kidney and Super Speciality Limited approved standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. Standalone profit after tax for Q3FY26 was ₹233.26 Lakhs, and for nine months was ₹853.36 Lakhs. Consolidated profit after tax for Q3FY26 was ₹370.62 Lakhs, and for nine months was ₹1,198.58 Lakhs.
Financial results are material information for investors and can influence investment decisions, thus having a medium impact.
The announcement reports financial results, which are routine for a listed company. While the results themselves may have positive or negative implications, the act of reporting them is neutral.
Gujarat Kidney and Super Speciality Limited announced the outcome of its Board Meeting held on February 14, 2026. The Board approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025, along with the Limited Review Report from the Statutory Auditors.
The standalone financial results for the quarter ended December 31, 2025, showed a profit after tax of ₹233.26 Lakhs. For the nine months ended December 31, 2025, the standalone profit after tax was ₹853.36 Lakhs.
On a consolidated basis, the company reported a profit after tax of ₹370.62 Lakhs for the quarter ended December 31, 2025. For the nine months ended December 31, 2025, the consolidated profit after tax stood at ₹1,198.58 Lakhs.
The Board meeting commenced at 5:00 PM IST and concluded at 6:00 PM IST. The financial results are also available on the company's website.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.